Today, Beactica Therapeutics is setting the pace in the cancer drug development landscape, with a strong focus on leveraging synthetic lethality to develop novel therapeutics for genetically defined cancers. This position at the forefront of the field, is rooted in Beactica’s unique heritage spanning decades of research and industrial development.
Prof. Helena Danielson at Uppsala University initiates collaboration with Biacore AB that results in adapting biosensor technology for small molecule drug discovery
Beactica AB is founded in Uppsala by Dr Per Källblad and Prof. Helena Danielson to pioneer fragment-based drug discovery using SPR biosensor technology
Beactica delivers key insights of the molecular interactions between Afatinib (Giotrif®) and its cellular targets to Boehringer Ingelheim
Beactica publishes platform validation on the identification of novel allosteric scaffolds to target HIV Reverse Transcriptase
Beactica enables the generation of the world's first highly potent and selective allosteric USP7 inhibitor that later is outlicensed by Almac to Genentech
Beactica and collaborators publish in PNAS on the identification of novel allosteric modulators for an important neuro target, further validating Beactica's platform
Beactica and Dong-A ST enter into license and collaboration agreement to develop novel cancer therapies targeting a family of epigenetic enzymes
Beactica delivers key insights into the complex binding interactions of biosimilar Insulin lispro Sanofi®, contributing towards its regulatory approval
Beactica receives the Nordic Stars Award in “recognition of outstanding innovation and entrepreneurial skill”
Beactica Therapeutics and Dong-A ST achieve a key milestone in their anti-cancer collaboration when a first-in-class protein–protein interaction inhibitor meets certain pre-defined lead criteria
Beactica Therapeutics and Oscotec and announce license and collaboration agreement to develop novel anti-cancer drug candidates arising out of Beactica’s LSD1 programme
This exceptional track record – in combination with the team's dedication to scientific excellence – has enabled Beactica to steadily advance its position in the pharmaceutical R&D value chain. Today, our vision is to become a clinical-stage precision oncology company with a pipeline of breakthrough therapeutics against genetically defined cancers. Read more about our pipeline here.
Sign up for the Beactica newsletter to receive our latest news and updates